Aquestive Therapeutics, Inc. (AQST)
| Previous Close | 4.5000 |
| Open | 4.3800 |
| Bid | 4.4200 x 200 |
| Ask | 4.5100 x 200 |
| Day's Range | 4.3102 - 4.4700 |
| 52 Week Range | 1.1500 - 6.2300 |
| Volume | |
| Avg. Volume | 2,448,364 |
| Market Cap | 401.707M |
| Beta (5Y Monthly) | 2.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings Date | Apr 30, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
GlobeNewswireAquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the
ZacksAquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
- GlobeNewswire
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct
